ONCAlert | Upfront Therapy for mRCC
Videos  >  

Shah Discusses Hope for CAR T-Cell Therapy in Multiple Myeloma

Nina Shah, MD
Published Online:8:09 PM, Tue January 14, 2020

Nina Shah, MD, an associate professor of Medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the question of whether chimeric antigen receptor (CAR) T-cell therapy is ready for primetime in patients with multiple myeloma.

Shah says it is not primetime for CAR T cells in multiple myeloma yet, but the reason for asking this question is because of the significant responses that have been demonstrated with CAR T cells already in this space. The therapy induced response rates around 85% to 90% in patients who are heavily pretreated with multiple myeloma, where the median number of prior lines is 7. These kind of response rates are unheard of in this patient population, Shah says, and CAR T-cell therapy is ultimately rescuing a lot of really sick patients.

To improve upon the current research in multiple myeloma, CAR T-cell therapy needs to move forward in the treatment sequence so that CAR T cells aren’t being used last-minute after patients have already failed multiple prior lines of therapy. Shah is happy that many groups are already considering moving CAR T-cell therapies earlier in the treatment landscape.
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.